Abdominal Ultrasound in the Detection of an Incidental Paraganglioma

Hsiao-Ting Chen1,2, Yung-Yin Cheng1,2*, Teng-Fu Tsao1,2, Cheng-Ming Peng1,4, Jeng-Dong Hsu1,2, Yeu-Sheng Tyan1,2,3

1Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan, 2Department of Medical Imaging and Radiological Sciences, Chung Shan Medical University, Taichung, Taiwan, 3School of Medicine, Chung Shan Medical University, Taichung, Taiwan, 4Division of General Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan, 5Department of Pathology, Chung Shan Medical University Hospital, Taichung, Taiwan

Abstract

Paraganglioma is a tumor that originates from neuroendocrine cells of the sympathetic or parasympathetic systems. Patients may suffer from headaches, palpitations, diaphoresis, and hypertension due to catecholamine excess or symptoms from the mass effect of the tumor. In the absence of typical symptoms of catecholamine excess, the diagnosis of a nonfunctional paraganglioma is often delayed. Herein, we report a case of a 63-year-old female patient with a nonfunctional paraganglioma which is an accidental finding during investigation of a fever. Abdominal ultrasonography incidentally detected this lesion as a complex, solid, cystic mass in the left suprarenal retroperitoneum.

Keywords: Paraganglioma, retroperitoneum, ultrasound

INTRODUCTION

Incidentaloma is a mass lesion that is discovered incidentally during a radiologic examination. Because of the widespread use of abdominal ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI), such imaging findings have been increasingly frequent.[1-3] “Incidentaloma” is used to describe a wide and heterogeneous spectrum of pathologies, including benign or malignant tumors, hormonally active or inactive lesions, metastases, infections, granulomas, infiltrations, cysts and pseudocysts, and hemorrhages.[1] We present the case of nonfunctional retroperitoneal paraganglioma discovered during investigation of a fever.

CASE REPORT

A 63-year-old female with a history of hypertension under medication control for 3 years went to the emergency department of our hospital because of fever and chills for 2 days. She went to the emergency department of our hospital because of fever and chills for two days. Physical examination disclosed a soft abdomen without flank knocking pain. Blood examination showed elevated C-reactive protein (14.8 mg/dL; normal < 0.7 mg/dL). Urinalysis was positive for leukocyte esterase and bacteria. The remaining systemic inquiry was unremarkable. There was no leukocytosis at presentation.

Abdominal US was performed to evaluate the urinary system and showed a mass lesion with cystic contents in the left upper retroperitoneum behind the pancreas and just lateral to the abdominal aorta [Figure 1]. Bilateral kidneys showed no hydronephrosis. The patient underwent abdominal CT that confirmed a mass lesion in the left retroperitoneal location that was very close to the left adrenal gland [Figure 2]. An incidentaloma was considered.

Antibiotic treatment was prescribed for the urinary tract infection, fever, and chills subsided. One month later, the patient underwent laparoscopic surgery, and the retroperitoneal incidentaloma about 6.4 cm × 5.5 cm was excised totally. Neither ascites nor retroperitoneal lymph node was noted. The left adrenal gland was free of the tumor. The pathology showed a paraganglioma [Figure 3]. The postoperative course
These tumors, which are usually hypointense compared with the liver parenchyma on T2-weighted images, exhibit similar appearances between functioning and nonfunctioning paragangliomas. 

Urine and plasma metanephrines, which are the biochemical marker called chromogranin A (CgA) that is now considered the more accurate test.

The classical presentation of a paraganglioma is excess catecholamine production. Paragangliomas produce, store, synthesize, and metabolize catecholamines. A value three times the upper range of normal is a positive result. However, because of fluctuating release of catecholamines, a false negative may occur in the low catecholamine level. Urine and plasma metanephrines, which are the metabolites of catecholamines, last more consistent in the body, so measurement of these metabolites in plasma is now considered the more accurate test. There is another biochemical marker called chromogranin A (CgA) that is used in patients with paraganglioma. CgA is a polypeptide commonly secreted by chromaffin cells, typically with catecholamines. In the absence of typical symptoms of catecholamine excess, diagnosis of a nonfunctional paraganglioma is often delayed.

Diagnostic imaging plays a critical role in paragangliomas. On US imaging, paragangliomas in the neck usually appear as hypoechoic, well-defined, inhomogeneous, hypervascular masses in the area of the carotid bifurcation, which separates the internal and external carotid arteries. However, there are few reports of US imaging of abdominal paragangliomas. Hashimoto et al. revealed eight abdominal paragangliomas (size range: 2.3–11.9 cm; median: 6.5 cm) and showed that six of eight were in contact with the inferior vena cava or pancreas. They found that all eight lesions had distinct boundaries with near-spherical (six of eight), polygonal (one of eight), or irregular (one of eight) shapes. Half of the lesions (four of eight) had predominantly cystic components, and seven of eight showed blood flow signals. In our case, the tumor was close to the pancreas and exhibited a well-defined margin and cystic change. We did not detect Doppler flow signals within the lesion, which may have been because of the high-velocity scan setting (53 cm) for which a high-flow vessel, such as the abdominal aorta, was not contaminated with aliasing artifacts, but the sensitivity to low blood flow within a tumor declines.

On contrast-enhanced CT, these tumors appear as paraaortic soft-tissue masses with either homogeneous contrast enhancement or central areas of low attenuation, as in our case. Compared with larger tumors, smaller ones are more likely to be homogeneous in attenuation and sharply marginated. Punctate calcification or focal areas of high attenuation caused by acute hemorrhage are seen in some tumors. On MRI, these tumors are usually hypointense or isointense compared with the liver parenchyma on T1-weighted images and are markedly hyperintense on T2-weighted images. Either CT or MRI images may exhibit similar appearances between functioning and nonfunctioning paragangliomas.

The diagnosis of malignant paraganglioma has stringent criteria according to the World Health Organization (WHO).
Hypointense or isointense to liver parenchyma. A common classification framework for some biochemical data are thought to be a factor to predict malignancy, but they remain controversial. The clinical, biochemical, and radiological features alone are inadequate to predict malignancy. Some biochemical data are thought to be a factor to predict malignancy, but they remain controversial. Concerning treatments for paraganglioma, patients with biochemically active paraganglioma should immediately be placed on antihypertensive medications to control symptoms and reduce the risk of hypertensive crises. After antihypertensive medications, treatment options are surgical resection, radiofrequency ablation, radiotherapy, chemotherapy, and molecular-targeted therapies; however, surgical resection remains the only curative treatment for patients with paragangliomas. A previous report described apparently benign disease that returned with metastases ≤15 years after resection, so life-long follow-up of patients with resected paragangliomas is imperative. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

### Table 1: Imaging characteristics of paragangliomas

| Image modality | Finding |
|----------------|---------|
| US | Distinct boundaries, various shapes (near-spherical in the majority), presence of blood flow signals, with or without cystic change |
| CT | Sharply margined, punctate calcification, with or without hemorrhage, homogeneous contrast enhancement in small tumors; central necrosis in large tumors |
| MRI | Hypointense or isointense to liver parenchyma T1-weighted images; markedly hyperintense on T2-weighted images |

classification in 2004 and requires evidence of metastases at nonchromaffin sites distant from the primary tumor, such as lymph nodes, bones, liver, and lung. However, the WHO classification changed in 2017. Currently, the term metastatic paraganglioma has replaced malignant paraganglioma. Previous reports have shown that the malignant rate of paragangliomas range from 7% to 50% and tumor malignancy can be diagnosis at the first presentation or during follow-up. In addition, Hamidi et al. reported that approximately 21% of malignant paragangliomas are nonfunctional tumors. The clinical, biochemical, and radiological features alone are inadequate to predict malignancy. Some biochemical data are thought to be a factor to predict malignancy, but they remain controversial. Concerning treatments for paraganglioma, patients with biochemically active paraganglioma should immediately be placed on antihypertensive medications to control symptoms and reduce the risk of hypertensive crises. After antihypertensive medications, treatment options are surgical resection, radiofrequency ablation, radiotherapy, chemotherapy, and molecular-targeted therapies; however, surgical resection remains the only curative treatment for patients with paragangliomas. A previous report described apparently benign disease that returned with metastases ≤15 years after resection, so life-long follow-up of patients with resected paragangliomas is imperative.

### References

1. Mirilas P, Skandalakis JE. Benign anatomical mistakes: Incidentaloma. Am Surg 2002;68:1026-8.
2. Chojnick R. Incidentalomas: Managing risks. Radiol Bras 2015;48:9-10.
3. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601-10.
4. Asa SL, Ezzat S, Mete O. The diagnosis and clinical significance of paragangliomas in unusual locations. J Clin Med 2018;7:280.
5. Lack EE. Atlas of tumor pathology. In: Tumors of the Adrenal Gland and Extraadrenal Paraganglia. Armed Forces Institute of Pathology. Vol. 8. Washington, DC, USA: American Registry of Pathology Press; 2007.
6. Alreizk R, Suarez A, Teni I, Pacak K. Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. Front Endocrinol (Lausanne) 2018;9:515.
7. Rha SE, Byun JY, Jung SE, Chun HJ, Lee HG, Lee JM. Neurogenic tumors in the abdomen: Tumor types and imaging characteristics. Radiographics 2003;23:29-43.
8. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770-86.
9. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore) 1991;70:46-66.
10. Bravo EL. Pheochromocytoma: New concepts and future trends. Kidney Int 1991;40:544-56.
11. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014;38:7-41.
12. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-42.
13. Grossman A, Pacak K, Sawka A, Lenders JW, Harlander D, Peaston RT, et al. Biochemical diagnosis and localization of pheochromocytoma: Can we reach a consensus? Ann N Y Acad Sci 2006;1073:332-47.
14. Eiden LE, Iacangelo A, Hsu CM, Hotchkiss AJ, Bader MF, Aunis D. Chromogranin A synthesis and secretion in chromaffin cells. J Neurochem 1987;49:65-74.
15. Schafani EM, Woodruff JM, Brennan MF. Extraadrenal retroperitoneal paragangliomas: Natural history and response to treatment. Surgery 1990;108:1124-9.
16. Lack EE, Cubilla AL, Woodruff JM, Lieberman PH. Extra-adrenal paragangliomas of the retroperitoneum: A clinicopathologic study of 12 tumors. Am J Surg Pathol 1980;4:109-20.
17. Dematté S, Di Sarra D, Schiavi E, Casadei A, Opoche G. Role of ultrasound and color Doppler imaging in the detection of carotid paragangliomas. J Ultrasound 2012;15:158-63.
18. Tong Y. Role of duplex ultrasound in the diagnosis and assessment of carotid body tumour: A literature review. Intractable Rare Dis Res 2012;1:129-33.
Chen, et al.: Sonogram of paraganglioma

19. Hashimoto M, Miyakishi M, Nakatani T, Nakajima Y, Kobayashi S, Ito U, et al., Study of ultrasound images of paragangliomas. Jpn. J Med Ultrasound Technol 2017;42:24-35.

20. Hayes WS, Davidson AJ, Grimley PM, Hartman DS. Extraadrenal retroperitoneal paraganglioma: Clinical, pathologic, and CT findings. AJR Am J Roentgenol 1990;155:1247-50.

21. Lee KY, Oh YW, Noh HJ, Lee YJ, Yong HS, Kang EY, et al. Extraadrenal paragangliomas of the body: Imaging features. AJR Am J Roentgenol 2006;187:492-504.

22. van Gils AP, Falke TH, van Erkel AR, Arndt JW, Sandler MP, van der Mey AG, et al. MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas. Radiographies 1991;11:37-57.

23. Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL. Pheochromocytoma and paraganglioma: Comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 1987;165:89-93.

24. DeLellis RA, Lloyd RV, Heitz PU, Eng C. WHO Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. 3rd ed. Lyon, France: International Agency for Research on Cancer (IARC); 2004. p. 159-60.

25. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2017. p. 179-206.

26. Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol 2017;28:213-27.

27. Goldstein RE, O’Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755-64.

28. Pommier RF, Vetto JT, Billingsly K, Woltering EA, Brennan MF. Comparison of adrenal and extraadrenal pheochromocytomas. Surgery 1993;114:1160-5.

29. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS. Long-term evaluation following resection of apparently benign pheochromocytomas/paragangliomas. World J Surg 1990;14:325-9.

30. Hamidi O, Young WF Jr., Iñiguez-Ariza NM, Kittah NE, Gruber L, Bancos C, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 2017;102:3296-305.

31. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milošević D, et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012;48:1739-49.

32. Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: Utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005;90:2068-75.

33. Poirier É, Thauvette D, Hogue JC. Management of exclusively dopamine-secreting abdominal pheochromocytomas. J Am Coll Surg 2013;216:340-6.

34. Andersen KF, Altaf R, Krakup-Hansen A, Kromann-Andersen B, Horn T, Christensen NJ, et al. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev 2011;37:111-9.